Pre-operative Chemotherapy for Non-small Cell Lung Carcinoma
Pre-operative Chemotherapy for Non-small Cell Lung Carcinoma
We reviewed an individual patient data meta-analysis by Burdett in 2014. This indicated that pre-operative chemotherapy improves OS (HR 0.87, 95% CI, 0.78–0.96, P=0.007) and RFS (HR 0.85, 95% CI, 0.76–0.94, P=0.002) for operable NSCLC compared with surgery alone. Although the current consensus recommends the use of post-operative chemotherapy, both strategies should be regarded as the first choice treatment options.
Conclusions
We reviewed an individual patient data meta-analysis by Burdett in 2014. This indicated that pre-operative chemotherapy improves OS (HR 0.87, 95% CI, 0.78–0.96, P=0.007) and RFS (HR 0.85, 95% CI, 0.76–0.94, P=0.002) for operable NSCLC compared with surgery alone. Although the current consensus recommends the use of post-operative chemotherapy, both strategies should be regarded as the first choice treatment options.
Source...